ArticleJournal of gastrointestinal oncology2025
Long-term outcomes of indeterminate focal hepatic observations less than 20 mm followed up with gadoxetic acid-enhanced magnetic resonance imaging (Gd-EOB-DTPA-MRI).
Article in Journal of gastrointestinal oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Indeterminate hepatic observations classified as Liver Imaging Reporting and Data System (LI-RADS) category 3 (LR-3) exhibit uncertain malignant potential and pose a diagnostic challenge during hepatocellular carcinoma (HCC) surveillance. Although most LR-3 observations remain stable, recent studies have reported variable progression rates to HCC. The purpose of the present study was to investigate and assess the clinical outcomes and progression-associated factors of LR-3 observations less than 20 mm in high-risk patients, on follow-up with serial gadoxetic acid-enhanced magnetic resonance imaging (Gd-EOB-MRI). Methods: A retrospective review was conducted on 125 patients with hepatitis B virus (HBV)-related cirrhosis who underwent Gd-EOB-MRI examinations at index and during follow-up. A total of 149 untreated LR-3 observations less than 20 mm in size were included in the study. Stepwise multivariate Cox proportional hazards model analysis was performed to identify the predictive risk factors for progression (upgraded to LR-4 or LR-5), including patient demographics and LI-RADS imaging features. Overall cumulative risk for progression was calculated using the Kaplan-Meier method, and significant predictive risk factors were compared using the log-rank test. Results: Over a median follow-up period of 18.3 months (range, 2.7-78.5 months), the overall cumulative risk of progression for LR-3 observations was 41.6% (62/149) and was 1.3%, 9.5%, 17.3%, and 37.3% at 3, 6, 12, and 24 months, respectively. The multivariate analysis revealed three significant independent predictors of progression: non-rim arterial phase hyperenhancement (APHE) [hazard ratio (HR) =2.19; P=0.005], subthreshold growth (HR =2.78; P=0.001), and mild-to-moderate T2 hyperintensity (HR =5.25; P<0.001). LR-3 observations with non-rim APHE or mild-to-moderate T2 hyperintensity showed a significantly higher cumulative risk of progression (53.3% Conclusions: Non-rim APHE, subthreshold growth, and mild-to-moderate T2 hyperintensity were significantly associated with an increased risk of progression among high-risk patients with LR-3 observations.. In particular, the presence of non-rim APHE or mild-to-moderate T2 hyperintensity was linked to both a higher cumulative incidence of progression and a shorter median interval to LR category upgrade.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.